Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research Note: Prospects for early detection of breast muscle myopathies by automated image analysis.

Poultry science·2024
Same author

In-ovo feeding with creatine monohydrate: implications for chicken energy reserves and breast muscle development during the pre-post hatching period.

Frontiers in physiology·2023
Same author

A deep learning-based automated image analysis for histological evaluation of broiler pectoral muscle.

Poultry science·2023
Same author

Supply and demand of creatine and glycogen in broiler chicken embryos.

Frontiers in physiology·2023
Same author

Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.

International journal of molecular sciences·2021
Same author

Farewell to Professor David Yaffe - A pillar of the myogenesis field.

European journal of translational myology·2020

Related Experiment Video

Updated: Jun 6, 2026

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

Halofuginone and muscular dystrophy.

Mark Pines1, Orna Halevy

  • 1Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel. pines@agri.huji.ac.il

Histology and Histopathology
|December 1, 2010
PubMed
Summary
This summary is machine-generated.

Halofuginone shows promise for treating muscular dystrophies (MDs) by reducing fibrosis and enhancing muscle cell fusion. This drug improves muscle function and histopathology, offering a supportive therapy for MD patients.

More Related Videos

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Area of Science:

  • Muscle Biology
  • Pharmacology
  • Genetics

Background:

  • Muscular dystrophies (MDs) are inherited disorders causing progressive muscle degeneration and impaired function.
  • Current research focuses on gene therapy, but no cure exists, necessitating supportive therapies.
  • Muscle fibrosis and degeneration are key pathological features in MDs.

Purpose of the Study:

  • To evaluate halofuginone as a supportive therapy for muscular dystrophies.
  • To investigate halofuginone's effects on muscle fibrosis and regeneration.
  • To explore halofuginone's impact on muscle cell fusion and function.

Main Methods:

  • Utilized animal models of MD with varying degrees of muscle fibrosis.
  • Administered halofuginone to assess its impact on collagen production and fibrosis.
  • Investigated halofuginone's effects on myotube fusion and associated signaling pathways (Akt, MAPK).

Main Results:

  • Halofuginone prevented collagen production in young MD models and resolved fibrosis in older ones.
  • Treatment led to improved muscle histopathology and significant functional recovery in MD models.
  • Observed enhanced myotube fusion in MD models, linked to Akt and MAPK pathway activation.

Conclusions:

  • Halofuginone demonstrates efficacy in improving muscle histopathology and function across different MD models.
  • The drug acts by inhibiting muscle fibrosis and promoting myotube fusion.
  • Halofuginone represents a promising complementary therapeutic strategy for MD patients.